Skip to main content
. Author manuscript; available in PMC: 2017 May 15.
Published in final edited form as: Cancer Res. 2016 Mar 17;76(10):2990–3002. doi: 10.1158/0008-5472.CAN-15-2931

Fig. 6. Inhibition of mTOR signaling pathway is critical for palbociclib-induced senescence in melanoma.

Fig. 6

(A) Western blot analysis of 1205Lu cells treated with rapamycin or palbociclib or both for 1, 4, or 8 days. (B) Immunohistochemistry of tumors derived +/− palbociclib. (C) Western analysis of 1205Lu cells +/− palbociclib,+/− MG132. (D) FACS analysis of 1205Lu cells infected with GFP (top panels) or ShRb1 (middle and bottom panel) treated with either rapamycin or palbociclib, or both followed by vemurafenib+palbociclib for 2 days (bottom panel). (E) Clonogenic assay of 1205Lu cells treated with rapamycin, palbociclib, or Rapamycin+palbociclib for 3 days (top panel) or 8 days (bottom panel). (F) Immunoblot of palbociclib-resistant 1205Lu cells.